Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial

By sjmartinez • June 4, 2025

Powles TB, Van der Heijden MS, Loriot Y, Bedke J, Valderrama BP, Iyer G, Kikuchi E, Hoffman-Censits J, Vulsteke C, Drakaki A, Rausch S, Arafat W, Park SH, Swami U, Li JR, Duran I, Gorla S, Homet Moreno B, Yu X, Lu YT, Gupta S. Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial. Ann Oncol. 2025 May 29:S0923-7534(25)00762-8. doi: 10.1016/j.annonc.2025.05.536. Epub ahead of print. PMID: 40460988.

Tags: antibody-drug conjugate, enfortumab vedotin, EV-302, Hematology/Oncology, overall survival, pembrolizumab, Progression-free survival, Publications

“Protected time” for clinical investigators in medical oncology: The persistent gap between expectation and reality

Sedrak MS, Ramalingam SS, Sparano JA. "Protected time" for clinical investigators in medical oncology: The persistent gap between expectation and reality. Cancer. 2026 Jul 1;132(13):e70499.[...]

Case Report: A case of HIV seroconversion in a high-risk individual after 35 years of resistance with a CCR5DELTA32 heterozygous genotype

Aziz N, Kim EY, Jamieson BD, Mimiaga MJ, Martinez J, Detels R. Case Report: A case of HIV seroconversion in a high-risk individual after 35[...]

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer

Tsvetkova O, Gil TE, Kassir G, Castanon S, Kollapaneni SS, Han A, Park SJ, Li R, Velez MA, Lisberg AE. Evaluating datopotamab deruxtecan (Dato-DXd) as[...]